Management of Exercise-Induced Hypertension
Diagnostic Confirmation
- The European Society of Cardiology recommends confirming the diagnosis with proper measurement technique, including using validated automated upper arm cuff devices with appropriate cuff size, obtaining multiple readings over 2-3 office visits, and considering home BP monitoring or 24-hour ambulatory monitoring 3, 1
- Measure BP in both arms simultaneously at the first visit and use the arm with higher readings for subsequent measurements 3
Risk Stratification
- At age 67, the patient is automatically considered high-risk for cardiovascular disease, which influences treatment decisions 3, 4
- Calculate 10-year atherosclerotic CVD risk using validated tools, such as the ASCVD calculator, QRISK2, or SCORE 3
Lifestyle Modifications
- The European Heart Journal recommends smoking cessation, as tobacco use independently causes CVD and mortality 1
Pharmacological Treatment Decision
- The European Society of Cardiology recommends prompt initiation of BP-lowering medication for confirmed BP ≥140/90 mmHg, irrespective of CVD risk 1, 2
First-Line Pharmacological Therapy
- Initiate combination therapy with a RAS blocker plus either a dihydropyridine calcium channel blocker or thiazide diuretic 1, 2
- For non-Black patients, a low-dose ACE inhibitor (e.g., lisinopril 10 mg daily) or ARB, plus a dihydropyridine calcium channel blocker (e.g., amlodipine 5 mg daily) is recommended 3, 4
Blood Pressure Targets
- Target systolic BP of 120-129 mmHg, provided treatment is well tolerated 1, 2, 4
- Aim to reduce BP by at least 20/10 mmHg from baseline 3, 4
Monitoring and Titration
- Reassess BP within 2-4 weeks after initiating therapy, using both office and home BP measurements 5, 3, 4
Common Pitfalls to Avoid
- Do not combine two RAS blockers (ACE inhibitor + ARB), as this increases adverse effects without additional benefit 1, 2
- Do not use beta-blockers as first-line therapy unless there are compelling indications 1, 2